RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women
- 144 Downloads
Men are more susceptible to gastric cancer (GC) than women. However, the genetic factors associated with the sex difference are not well understood. Chemokines have been shown to modulate tumor behavior, and the sex-specific effect of the chemokine polymorphisms on the host susceptibility to several diseases has been reported. We aimed to determine the role of chemokine polymorphisms on host susceptibility to GC, with special interest on their sex-specific effect.
A hospital-based case-control study, including 177 patients with GC and 217 age-matched unaffected healthy controls, was performed in three major tertiary care hospitals. Genotyping for regulated upon activation, normal T-cell expressed and secreted (RANTES) −403 A/G and −28 C/G, CC chemokine receptor 5 (CCR5) deletion, and CCR2-V64I was performed using peripheral blood DNA.
The RANTES −403 GA and AA genotypes were independently associated with a 2.3-fold reduced risk of developing GC (OR = 0.44, 95% CI 0.22–0.90, P = 0.025) compared with GG genotype in women, but not in men. The RANTES −28C/G and CCR2-V64I polymorphisms were not associated with different risk of developing GC. The tumor stage, histological features, and survival rate were not different when stratified by RANTES −403 and −28 and CCR2-V64I genotypes.
Our data indicate that women who inherit A allele at RANTES −403 may be at reduced risk of GC.
Key wordsgastric cancer RANTES CCR5 CCR2 chemokine polymorphism women
Unable to display preview. Download preview PDF.
- 28.Nahon P, Sutton A, Rufat P, Faisant C, Simon C, Barget N, et al. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepatol 2007;19:425–431.PubMedCrossRefGoogle Scholar
- 29.Lindblad M, Ye W, Rubio C, Lagergren J. Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden. Cancer Epidemiol Biomark Prev 2004;13:2203–2207.Google Scholar